The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.
September 27th 2024
Shyam A. Patel, MD, PhD, discusses findings from a meta-analysis of the effect of clonal hematopoiesis on outcomes for hematopoietic stem cell transplant.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Community Oncology Connections™: Selecting and Sequencing Therapy for Patients With DLBCL in an Era of Expanding Options
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Quizartinib Plus Chemo Significantly Improves OS Vs Chemo Alone in Newly Diagnosed FLT3-ITD+ AML
The addition of quizartinib to standard induction and consolidation chemotherapy and then continued as a single agent doubled median overall survival vs standard chemotherapy alone in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.
PRO Results Show Zanubrutinib Improves HRQOL Vs Ibrutinib in R/R CLL/SLL
Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic leukemia assigned to zanubrutinib reported better health-related quality of life than those administered ibrutinib.
Epcoritamab Plus GemOX Exhibits Promising Early Efficacy in R/R DLCBL
Epcoritamab in combination with gemcitabine plus oxaliplatin displayed encouraging responses with no new safety signals among patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant, according to initial results from the phase 1b/2 EPCORE NHL-2 trial.
Epcoritamab Plus R-DHAX/C Demonstrates High Response Rates and Manageable Safety in DLBCL
June 10th 2022Epcoritamab plus rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin displayed encouraging responses in patients with relapsed/refractory diffuse large B-cell lymphoma who are eligible for autologous stem cell transplant, according to preliminary results from arm 4 of the phase 1b/2 EPCORE NHL-2 trial.
NPM1 Mutations, MRD Responses Linked to Long-Term Survival Benefits With Azacitidine in AML
Oral azacitidine was associated with improved long-term survival in patients with acute myeloid leukemia who harbored NPM1 mutations, had intermediate-risk cytogenetics at diagnosis, had a longer treatment duration, or a minimal residual disease response during treatment.
Considerations for Venetoclax + Azacitidine Administration and AE Management
June 9th 2022Richard Stone, MD, and Eunice Wang, MD, discuss considerations and challenges related to the administration of venetoclax and azacitidine in the community setting, and share strategies for managing adverse events associated with this combination.
Mosunetuzumab Approved in Europe for Relapsed/Refractory Follicular Lymphoma
The European Commission has granted a conditional marketing authorization for mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 systemic therapies.
Asciminib Represents New Standard of Care for Patients With CML in Chronic Phase
June 7th 2022Asciminib continued to demonstrate durable, major molecular responses as well as a tolerable safety profile vs bosutinib suggesting a long-term benefit in adult patients with chronic myelogenous leukemia in chronic phase who have been previously treated with 2 tyrosine kinase inhibitors.
Key Subgroup Analyses Supports Tafasitamab Plus Lenalidomide for High-Risk R/R DLBCL
Treatment with tafasitamab plus lenalidomide demonstrated trends toward improved overall survival vs systemic regimens across key subgroups of patients with high-risk relapsed or refractory diffuse large B-cell lymphoma who are not eligible for transplant, according to findings from an observational, retrospective analysis of the cohort RE-MIND2 study.
Liso-cel Elicits Significant Second-line Activity in Frail Patients with Relapsed/Refractory LBCL
June 5th 2022Treatment with lisocabtagene maraleucel resulted in a high rate of durable overall and complete responses as second-line therapy in frail patients with relapsed/refractory large B-cell lymphoma for whom hematopoietic stem cell transplantation was not intended, according to preliminary findings from the phase 2 PILOT study.
RVd Plus Transplant and Lenalidomide Maintenance Improves PFS in Newly Diagnosed Myeloma
June 5th 2022The combination of lenalidomide (Revlimid), bortezomib, and dexamethasone (RVd) plus autologous stem cell transplant as initial therapy followed by lenalidomide maintenance demonstrated a significant improvement in progression-free survival vs RVd alone followed by lenalidomide maintenance in patients with newly diagnosed multiple myeloma.
Epcoritamab Plus R2 Elicits High Metabolic Response Rate in Relapsed/Refractory Follicular Lymphoma
The addition of subcutaneous epcoritamab to treatment with rituximab and lenalidomide resulted in a 100% response rate and a low incidence of low-grade cytokine release syndrome in patients with relapsed/refractory follicular lymphoma, according to findings from arm 2 of the EPCORE NHL-2 trial.
BTX-1188 Demonstrates Safety Benefits, Enters Phase 1 Trials in AML and Solid Tumors
June 4th 2022BTX-1188, a first-in-class oral molecular glue, is undergoing investigation in phase 1 clinical trials in patients with solid tumors or acute myeloid leukemia, after preclinical trials supported its potential safety benefits in this population and demonstrated its high sensitivity in Myc-driven cancer cell lines.
Epcoritamab Plus R-CHOP Shows Efficacy and Tolerability as First-Line Treatment for High-Risk DLBCL
June 4th 2022The addition of subcutaneous epcoritamab to standard-of-care R-CHOP demonstrated clinically meaningful response in the first-line treatment of patients with high-risk diffuse large B-cell lymphoma according to updated results of a single-arm of the EPCORE NHL-2 trial.
Addition of Ivosidenib to Azacitidine Improves Outcomes in Newly Diagnosed IDH1-Mutant AML
The combination of ivosidenib and azacitidine elicited a clinically meaningful benefit across end points compared with azacitidine alone among patients with newly diagnosed IDH1-mutant acute myeloid leukemia who were ineligible for intensive induction chemotherapy.
Glofitamab Demonstrates Durable Response in Heavily Pretreated Large B-Cell Lymphoma
Glofitamab elicited an objective response rate of 51.6% when administered for a fixed duration among patients with patients with heavily pretreated, highly refractory large B-cell lymphoma, regardless of prior CAR T-cell therapy exposure, according to findings from a phase 2 expansion study.
Frontline Brentuximab Vedotin Plus Chemotherapy Improves 6-Year Survival in Hodgkin Lymphoma
June 3rd 2022Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine demonstrated a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, with a manageable safety profile consistent with prior findings in patients with previously untreated stage III/IV classical Hodgkin lymphoma.
Sugemalimab Shows Promise for Natural Killer/T-cell Lymphoma
Treatment with the anti–PD-L1 IgG4 antibody sugemalimab resulted in a response for nearly half of patients and a complete response in one-third of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma.
Rolling Submission of BLA to FDA Completed for Omidubicel in Blood Cancers Requiring Transplant
The rolling biologics license application submission to the FDA to support the approval of omidubicel for patients with blood cancers in need of allogenic hematopoietic stem cell transplant has been completed.